Psyence Biomedical (PBM) announced that it has progressed beyond the previously-announced non-binding Letter of Intent, LOI, and executed binding agreements with Optimi Health Corp. Under the terms of the agreements, Optimi becomes the exclusive supplier of GMP-certified, nature-derived (non-synthetic) psilocybin extract for Psyence’s global drug development and commercialization initiatives for FDA-approved uses in the Palliative Care context. Optimi will provide comprehensive Chemistry, Manufacturing, and Control support for regulatory submissions related to Psyence’s clinical trials in Palliative Care and any future Investigational New Drug applications. Psyence will obtain exclusive rights to Optimi’s drug candidate for treatment use in the Palliative Care context.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PBM:
- Psyence Biomedical Boosts Equity to Meet Nasdaq Rules
- Psyence Biomedical Revises Debt-for-Equity Deal
- Psyence Biomed Strengthens Position with Valuable Stake and Trials
- Psyence Biomedical issues letter to shareholders
- Psyence Biomedical Ltd trading halted, news pending
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
